Objective:

To report a rare case of concurrent small cell lung cancer (SCLC) following glioblastoma (GBM) recurrence and explore tailored chemoradiotherapy strategies, emphasizing its significance in the context of existing literature.

Key Findings:

• The patient achieved a progression-free survival of 10 months after SCLC diagnosis, indicating potential effectiveness of the treatment strategy.
• Overall survival from initial GBM diagnosis was 58 months, exceeding typical prognoses for either cancer, suggesting a need for further exploration of similar cases.
• Treatment was well-tolerated with no grade ≥3 adverse events, underscoring the safety of the tailored approach.

Interpretation:

This case suggests that a personalized concurrent chemoradiotherapy strategy may effectively manage dual malignancies and improve survival outcomes.

Limitations:

• The rarity of concurrent GBM and SCLC limits generalizability, necessitating caution in applying findings to broader populations.
• Lack of molecular profiling at initial GBM diagnosis may affect treatment insights, highlighting the need for comprehensive profiling in future cases.

Conclusion:

An individualized treatment approach may provide meaningful survival benefits in patients with concurrent GBM and SCLC, warranting further investigation into personalized treatment strategies.